Inclusion Criteria:

          1. Male or female patients aged less than 18 or more than 65 years

          2. Patients who received allo-SCT for relapse after autologous transplantation for
             Hodgkin's lymphoma

          3. Patients who received tandem autologous and allogeneic stem cell transplantation for
             HL are eligible

          4. Histologically confirmed CD30+ classical Hodgkin lymphoma according to local
             pathologist (excluding nodular lymphocyte predominant subtype)

          5. Patients with Ann Arbor stage II-III or IV or extranodal localization at relapse post
             ASCT

          6. Patients who previously received Bv may be included if the duration of response to
             initial Bv treatment is more than 3 months

          7. Patients who previously received anti-PD1 drugs can be included

          8. Voluntary written informed consent must be given before performance of any
             study-related procedure not part of standard medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to future
             medical care.

          9. Patients must be covered by a social security system

         10. Female patients is either post-menopausal for at least 1 year before the screening
             visit or surgically sterile or if of childbearing potential, agree to practice 2
             effective methods of contraception, at the same time, from the time of signing the
             informed consent through 6 months after the last dose of study drug

         11. Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to
             practice effective barrier contraception during the entire study period and through 6
             months after the last dose of study drug.

         12. Performance status less or equal to 2

        Exclusion Criteria:

          1. Patients with histologically confirmed nodular lymphocyte predominant subtype

          2. Female patient who are both lactating and breast-feeding or have a positive serum
             pregnancy test during the screening period or a positive pregnancy test on Day 1
             before first dose of study drug

          3. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to the protocol.

          4. Known cerebral or meningeal disease (HL or any other etiology), including signs or
             symptoms of PML

          5. Unstable diabetes mellitus (to avoid uninterpretable FDG-PET scan).

          6. Symptomatic neurologic disease compromising normal activities of daily living or
             requiring medications

          7. Any sensory or motor peripheral neuropathy greater than or equal to Grade 2

          8. Known history of any of the following cardiovascular conditions

             Myocardial infarction within 2 years of enrollment :

               -  New York Heart Association (NYHA) Class III or IV heart failure

               -  Evidence of current uncontrolled cardiovascular conditions, including cardiac
                  arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic
                  evidence of acute ischemia or active conduction system abnormalities

               -  Recent evidence (within 6 months before first dose of study drug) of a
                  left-ventricular ejection fraction less than 50%

          9. Any active systemic viral, bacterial, or fungal infection requiring systemic
             antibiotics within 2 weeks prior to first study drug dose

         10. Patients that have not completed any prior treatment chemotherapy and/or other
             investigational agents within at least 5 half-lives of last dose of that prior
             treatment

         11. Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient
             contained in the drug formulation of Bv.

         12. Known human immunodeficiency virus (HIV) positive

         13. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C
             infection

         14. Diagnosed or treated for another malignancy within 3 years before the first dose or
             previously diagnosed with another malignancy and have evidence of residual disease.
             Patients with non-melanoma skin cancer or carcinoma in situ of any type are not
             excluded if they have undergone complete resection.

         15. Patient who presented intolerance to Bv

         16. Patient enrolled in other clinical research